FDA Wants New Warnings for Arthritis Drugs

According to a recent Reuters article, the FDA has asked three major drug companies to update safety restrictions for their arthritis drugs. The drugs in question belong to the class of treatments known as JAK inhibitors, which treat rheumatoid arthritis. All three drugs: Pfizer’s Xeljanz, AbbVie’s Rinvoq, and Eli Lilly’s Olumiant, currently have boxed warnings about blood clots and lymphoma. With updated warnings, the FDA is essentially pushing back the drugs’ place in the treatment sequence and limiting their use.